30
Participants
Start Date
July 1, 2017
Primary Completion Date
August 1, 2029
Study Completion Date
August 1, 2036
GPC3 and/or TGFβ targeting CAR-T cells
Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
RECRUITING
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
RECRUITING
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Hunan Zhaotai Yongren Medical Innovation Co. Ltd.
OTHER
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER